Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline
During the event, the company will highlight updates on the clinical development of GDA-201, its lead cryopreserved, off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large b-cell lymphomas, and Gamida Cell’s new development programs leveraging next-generation, NAM-enabled, genetically modified NK cells in development for solid tumors and hematological cancers. Specifically,
- GDA-301, a CISH knockout and membrane-bound IL-15 NK cell construct that has demonstrated increased potency against leukemia and multiple myeloma cell lines
- GDA-501, a CAR-HER2 NK cell construct that has shown increased cytotoxicity against an ovarian tumor cell line
- GDA-601, a CD38 knockout + CD38 CAR NK cell construct that has yielded increased cytotoxicity against a multiple myeloma cell line
The event will feature management presentations and participation by the following speakers:
Jeff Miller, M.D., Professor of Medicine, Division of Hematology, Oncology and Transplantation at University of Minnesota
Veronika Bachanova, M.D., Ph.D., Hematologist/Oncologist at
University of Minnesota Health
- Patient treated with GDA-201
The live event will be available at the following link. A replay of the webcast will be available on the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.
GDA-201 is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates, anticipated regulatory filings (including the submission of the BLA for omidubicel to the FDA), commercialization planning efforts, the potentially life-saving or curative therapeutic and commercial potential of omidubicel, and Gamida Cell’s expectations regarding its projected cash to be used for operating activities and cash runway. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 20-F, filed with the
1Bachanova, et al. ASH 2020. Abstract #63.
Stern Investor Relations, Inc.